|
|
TICK-BORNE DISEASE - UNITED STATES OF AMERICA: BACKGROUND
*********************************************************
A ProMED-mail post
<http://www.promedmail.org>
ProMED-mail is a program of the
International Society for Infectious Diseases
<http://www.isid.org>
Date: Fri 24 Oct 2008
Source: The gideon Database (www.GideonOnline.com) [edited]
<http://www.gideononline.com/blog/2008/10/24/increase-in-tick-borne-diseases-usa/>
Increase in tick-borne diseases, USA
------------------------------------
Rates of tick-borne infection in the United States have been
increasing dramatically since 2000. See graph at
<http://exhibit.gideononline.com/Tick-USA.jpg>
(Lyme disease displayed as cases/100 000 to allow fit).
Although this phenomenon might reflect changes in human exposure
dynamics and artifacts of reporting and diagnosis, I suspect that
these data are related to
increasing tick and animal reservoir populations.
--
Communicated by:
Steve Berger
Geographic Medicine
Tel Aviv Medical Center
<mberger@post.tau.ac.il>
[ProMed-mail thanks Steve Berger for drawing attention to the recent
increased frequencies in the United States of the tick-borne
diseases: Human monocytic erlichiosis, Human granulocytic
erlichiosis, Rocky Mountain spotted fever and Lyme disease. - Mod.CP]
[Some 20+ years ago I carried out various surveys for bovine
anaplasmosis as well as my students' research. Then it had a
prevalence of around 3 percent in Louisiana because it was dependent
on haemophagous flies (horse flies) for transmission. These flies must
refeed within 2 hours to transmit this pathogen before it dies, hence
the low prevalence. We had lost our one-time heavy tick infestations
thanks to 'fire' ants (_Solenopsis invicta_) which are now found from
Florida to California, munching on ticks and anything else they can
find. Latterly they have breached the frost line and are progressing north.
This will impact on the ability of human infections (and pathogens)
to spread. It would be worth investigating if these human infections
are presently spreading or not, and their reservoirs. - Mod.MHJ]
[see also:
Anaplasmosis, human granulocytic - USA: (MN), ex transfusion 2007
20081024.3362
Anaplasmosis, human granulocytic - Canada: 1st rep., (AB) 20080731.2352
2007
----
Ehrlichiosis, fatal - USA (MO) 20070607.1849
2003
----
Ehrlichiosis, human granulocytic - USA (MA) 20030903.2211
Ehrlichiosis, human monocytic - USA (NC) 20030625.1571
1999
----
Ehrlichiosis, human - Mexico 19990713.1173
1998
----
Ehrlichiosis, human granulocytic - USA (Connecticut) 19980713.1318
Ehrlichiosis, human granulocytic - Sweden 19980418.0719
1995
----
Human granulocytic ehrlichiosis (5) 19950802.0625
Human granulocytic ehrlichiosis - Europe? 19950723.0581]
.........................cp/ejp/mhj/jw
*##########################################################*
************************************************************
ProMED-mail makes every effort to verify the reports that
are posted, but the accuracy and completeness of the
information, and of any statements or opinions based
thereon, are not guaranteed. The reader assumes all risks in
using information posted or archived by ProMED-mail. ISID
and its associated service providers shall not be held
responsible for errors or omissions or held liable for any
damages incurred as a result of use or reliance upon posted
or archived material.
************************************************************
Become a ProMED-mail Premium Subscriber at
<http://www.isid.org/ProMEDMail_Premium.shtml>
************************************************************
Visit ProMED-mail's web site at <http://www.promedmail.org>.
Send all items for posting to: promed@promedmail.org
(NOT to an individual moderator). If you do not give your
full name and affiliation, it may not be posted. Send
commands to subscribe/unsubscribe, get archives, help,
etc. to: majordomo@promedmail.org. For assistance from a
human being send mail to: owner-promed@promedmail.org.
############################################################
############################################################
|